David Drobne - Concepedia

Author

David Drobne

Ljubljana University Medical Centre ORCID

Also Known As

D Drobne, D. Drobne, David Drobne, Drobne, David, Martin Laclav

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Ljubljana University Medical Centre University of Ljubljana KU Leuven Tel Aviv University University of Szeged

About

David Drobne is an author at Ljubljana University Medical Centre specializing in immunology, medicine, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	373
2	Immunology	6	6	373
3	Gastroenterology	5	5	239
4	Allergy	2	2	148
5	Pathology	1	1	11

David Drobne

Publications

929

Citations

H-Index

Page 1

	Year	Citations
Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy Filip Baert, David Drobne, Ann Gils, Clinical Gastroenterology and Hepatology Trough LevelsAutoimmune DiseaseAllergyInfliximab Predict SafetyImmunology	2014	134
Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease David Drobne, Peter Bossuyt, Christine Breynaert, Clinical Gastroenterology and Hepatology InflammationChronic Inflammatory DiseasesCo-treatment DoesAnti-inflammatoryReduce Trough Level	2014	131
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy Uri Kopylov, Jurij Hanžel, Claire Liefferinckx, Alimentary Pharmacology & Therapeutics	2020	78
Down‐regulation of micro<scp>RNA</scp>s of the <i>miR‐200</i> family and up‐regulation of Snail and Slug in inflammatory bowel diseases — hallmark of epithelial−mesenchymal transition Nina Zidar, Emanuela Boštjančič, Miha Jerala, Journal of Cellular and Molecular Medicine	2016	65
Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study Henit Yanai, A Kagramanova, O. V. Knyazev, Journal of Crohn s and Colitis	2022	59
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission Jurij Hanžel, Jurij Zdovc, Tina Kurent, Clinical Gastroenterology and Hepatology ImmunologyGastroenterologyBiochemical RemissionAchieve EndoscopicClinical Gastroenterology	2020	51
Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective Laimas Virginijus Jonaitis, Srdjan Marković, Klaudia Farkas, BMC Proceedings	2021	48
Success and safety of high infliximab trough levels in inflammatory bowel disease David Drobne, Tina Kurent, Saša Golob, Scandinavian Journal of Gastroenterology	2018	46
Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease David Drobne, Tina Kurent, Saša Golob, Alimentary Pharmacology & Therapeutics	2019	40
Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus—A Multicenter Retrospective Study Uri Kopylov, Konstantinos Papamichael, Matti Waterman, Inflammatory Bowel Diseases	2017	37

Page 1